Anatomical Therapeutic Chemical • L04AE01 • fingolimoda

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AE01 fingolimoda Indicated for: multiple sclerosis

L04AE02 ozanimod Indicated for: multiple sclerosis; ulcerative colitis

L04AE03 siponimod Indicated for: multiple sclerosis

L04AE05 etrasimod Indicated for: inflammatory bowel disease

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various